Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Kimberly Helms

Registered Nurse, Psychiatric/Mental Health Clayton, NC Nurse Practitioner

NPI 1629726229 CMS profile 11372392

8838 Clayton Blvd Ste 700, Clayton, NC 27520

Open in the dashboard

General payments

$9,039

354 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kimberly Helms of Clayton, NC is reported in the CMS Open Payments database as having received $9,039 across 354 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Registered Nurse, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,626 106
2024 General $5,691 144
2023 General $1,600 98
2022 General $123 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kimberly Helms
  • Registered Nurse, Psychiatric/Mental Health median
  • Middle half of Registered Nurse, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Kimberly Helms were reported at $1,626. Among 280 Registered Nurse, Psychiatric/Mental Health profiles paid that year, the median was $140 and the middle half received between $43 and $515.

Show as a table
Year Kimberly Helms Registered Nurse, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $101 $31–$244 $132
2022 $123 $103 $36–$248 $149
2023 $1,600 $138 $45–$382 $160
2024 $5,691 $167 $39–$462 $164
2025 $1,626 $140 $43–$515 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Almatica Pharma LLC $3,540 18 payments
  2. Otsuka America Pharmaceutical, Inc. $806 48 payments
  3. AbbVie, Inc. $682 56 payments
  4. Alkermes, Inc. $649 38 payments
  5. ITI, Inc. $640 37 payments
  6. Janssen Pharmaceuticals, Inc $451 27 payments
  7. Lundbeck LLC $389 21 payments
  8. Teva Pharmaceuticals USA, Inc. $359 18 payments
  9. Corium, Inc. $274 15 payments
  10. Supernus Pharmaceuticals, Inc. $227 21 payments
  11. Other $1,023 55 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $5,518 341 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,383 11 payments
  3. Education $139 2 payments
Products named General payments · program years 2022–2025
  1. LOREEV XR $3,540 18 payments
  2. LYBALVI $649 38 payments
  3. ARISTADA Cns $572 33 payments
  4. ARISTADA Cns $572 33 payments
  5. REXULTI Psychiatry $551 30 payments
  6. ARISTADA Cns $550 32 payments
  7. ARISTADA Cns $550 32 payments
  8. CAPLYTA $539 33 payments
  9. SPRAVATO $406 25 payments
  10. REXULTI Psychiatry $389 21 payments
  11. Other $3,159 207 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

30

Median for Registered Nurse: 109

Drug cost

$215

Median for Registered Nurse: $4,454

Branded share of claims

0%

Median for Registered Nurse: 15.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buspirone Hcl Generic 19 $115
Alprazolam Generic 11 $100

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 476 Part D prescribers listed as Registered Nurse; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LOREEV XR
  • Almatica Pharma LLC $3,512
$3,512 — —
CAPLYTA
  • ITI, Inc. $386
$386 — —
REXULTI
  • Lundbeck LLC $178
  • Otsuka America Pharmaceutical, Inc. $169
$347 — —
ARISTADA
  • Alkermes, Inc. $246
$246 — —
VRAYLAR
  • AbbVie, Inc. $212
$212 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

354 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Registered Nurse, Psychiatric/Mental Health in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record